OncoSpherix
OncoSpherix, Inc.: Advancing novel cancer treatments with proprietary therapeutics to enhance survival and quality of life.
Founded
2018OncoSpherix, Inc.: Advancing novel cancer treatments with proprietary therapeutics to enhance survival and quality of life.
OncoSpherix, Inc., founded in Atlanta, Georgia, is a pre-clinical stage oncology drug development company dedicated to improving the quality of life and survival rates for cancer patients. The company's core mission is to develop first-in-class small molecule therapeutics that target hypoxia-inducible factor-1 (HIF-1), a common feature in solid tumors due to their rapid growth outpacing blood supply. OncoSpherix focuses on creating innovative treatments for various forms of cancer, aiming to address the challenges of advanced cancers through combination therapies.
Notable figures affiliated with OncoSpherix include leading scientists and industry experts who contribute to its pioneering research and development efforts. The company has garnered attention from prominent investors in the biotech sector, supporting its mission-driven science. Key achievements include significant advancements in pre-clinical studies, positioning OncoSpherix as a promising player in oncology drug development. The overall impact of OncoSpherix lies in its potential to revolutionize cancer treatment by offering novel therapies that enhance patient outcomes and quality of life.
Companies similar to OncoSpherix include Oncofactor, Eris Biotech, OnCusp Therapeutics and Sisu Pharma.
OncoSpherix was founded in 2018.
OncoSpherix's headquarters is located in Atlanta, GA, US.
OncoSpherix's most recent funding round was for $2M (USD) in April 2023.
As of Apr 1, 2023, OncoSpherix has disclosed funding of $2.9M (USD). Undisclosed round amounts are excluded.
OncoSpherix has 3 employees as of Feb 4, 2024.
Sisu Pharma
sisupharma.com
